Immunotherapy in gastric cancer with liver metastasis:Challenges and opportunities  

作　　者：Murat Bardakçi Yakup Ergun 

机构地区：[1]Department of Medical Oncology,Diyarbakır Gazi Yasargil Training and Research Hospital,Diyarbakir 021000,Kayapinar,Türkiye [2]Department of Medical Oncology,Antalya City Hospital,Antalya 07080,Türkiye

出　　处：《World Journal of Gastrointestinal Surgery》2024年第6期1513-1516,共4页世界胃肠外科杂志（英文版）（电子版）

摘　　要：In this editorial,we review the article by Liu et al published in the World Journal of Gastrointestinal Surgery investigating the efficacy and safety of immunotherapy in patients with gastric cancer(GC)and liver metastasis.GC,the fifth most com-monly diagnosed malignancy worldwide,presents a significant challenge due to its multifactorial etiology and a grim prognosis for unresectable or recurrent cases.The advent of immune checkpoint inhibitors(ICIs)has revolutionized oncology;yet liver metastasis has been associated with reduced response rates,progression-free survival,and overall survival in various malignancies.The Che-ckMate-649 and KEYNOTE-859 trials demonstrated promising results with ICIs in advanced GC,particularly in patients with liver metastasis.However,a meta-analysis of liver metastatic solid tumors revealed worse outcomes with ICIs,high-lighting the need for further investigation.While combined therapies,including ICIs with local treatments,show promise in improving outcomes,the nuanced landscape of ICIs in liver metastatic GC necessitates continued research for robust conclusions.The current contradictions in the literature underscore the impor-tance of cautious interpretation and the exploration of tailored approaches to enhance clinical efficacy in this challenging patient population.

关 键 词：Gastric cancer Liver metastasis IMMUNOTHERAPY Immune checkpoint in-hibitors Transarterial chemoembolization Tumor microenvironment 

分 类 号：R730.51[医药卫生—肿瘤]